Press Release - Oslo, Norway, May 18, 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces the conclusion of a productive AUA 2022
Conference: the American Urological Association Annual Congress 2022, an in
-person event for the first time since 2019, was held May 13-16, 2022 in New
Orleans, LA, USA. Both the Photocure and Karl Storz exhibit booths provided
information to AUA attendees on the New Blue Light equipment, for which interest
was strong. During the program, a poster by Dr. Sia Daneshmand was presented on
restaging TURBTs in NMIBC* featuring Photocure's Cysview[®] product.

The American Urological Association (AUA) meeting is one of largest
international meetings in the urology calendar. The yearly event includes an
innovative, evidence-based, quality program for urologists and urologic health
care professionals worldwide.

The New Blue Light equipment from Karl Storz was prominently displayed on the
exhibition floor, as urologists visited both the Photocure and Karl Storz booths
to inquire about the New Blue Light System, the next generation equipment in
bladder cancer detection. The Karl Storz equipment is the only FDA approved
device for BLC with Cysview in the U.S. Physicians were able to get hands on
experience with the new system at the Karl Storz booth.

"We have been working closely with Karl Storz for several months to support a
successful launch of the New Blue Light system and were very pleased with the
interest expressed among uro-oncologists who visited our booth on the exhibition
floor. We were able to share some of the key features and benefits of The New
Blue Light and liaised with the Karl Storz team for firsthand demonstrations.
Given the positive feedback during AUA, we anticipate that several launch events
will support the education and practice needs for the urology community.
Additionally, Photocure prominently displayed the Flexible BLC system at its
booth. The positive feedback from uro-oncologists further reinforces the recent
surge in flexible blue light tower installations and how outpatient surveillance
with flexible BLC helps support the continuum of care for patients with bladder
cancer." said Geoff Coy, Vice President & General Manager North America.

This year's AUA program also once again featured NMIBC topics including Blue
Light Cystoscopy. A poster from Dr. Sia Daneshmand was presented entitled "Is a
Restaging TURBT** Necessary in Non-Muscle Invasive Bladder Cancer if the Initial
TURBT was Performed Using Blue Light?" This podium poster presentation
highlighted that patients who underwent BLC for their initial TURBT had more
benign pathology upon a restaging TURBT compared to WLC, though a restaging
TURBT is still advised. Dr. Sia Daneshmand, M.D., is Professor of Urology with
Clinical Scholar designation and serves as director of clinical research as well
as the urologic oncology (SUO) fellowship director at the University of Southern
California (USC) in Los Angeles.
Read the abstract here:
https://www.eventscribe.net/2022/AUA2022/fsPopup.asp?Mode=presInfo&PresentationI
D
=1051890

*NMIBC: Non-muscle invasive bladder cancer

**TURBT: Transurethral resection of bladder tumor


Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019